Physician profile
Jonathan M Morse
NPI 1265461784
$673.27
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $141 · 2021: $173.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $156.32 | 2019 | |
| Amgen INC. | $148.13 | 2019-2020 | |
| Abbvie INC. | $120.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.81 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $40.43 | 2021 | |
| Astellas Pharma US INC | $26.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.25 | 2019 | |
| Sanofi Pasteur INC. | $16.42 | 2020 | |
| Biodelivery Sciences International, INC. | $15.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2019 | |
| Merck Sharp & Dohme LLC | $14.02 | 2019 | |
| Allergan, INC. | $12.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.